Form 8-K - Current report:
SEC Accession No. 0000950170-25-066397
Filing Date
2025-05-08
Accepted
2025-05-08 07:36:02
Documents
13
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nuvl-20250508.htm   iXBRL 8-K 50701
2 EX-99.1 nuvl-ex99_1.htm EX-99.1 97882
3 GRAPHIC img8926856_0.jpg GRAPHIC 26288
  Complete submission text file 0000950170-25-066397.txt   319051

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20250508.xsd EX-101.SCH 31920
16 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20250508_htm.xml XML 4703
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 25923920
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)